). Viral vector is a critical component used in the
manufacturing of CAR T cells, and third-generation lentiviral vectors offer improved safety over
earlier generations1
I personally know someone that had a first generation CAR T after chemotherapy failed. To say that the side effect's were horrific is a big understatement.
It really was terrible for that person, and many others I'm sure.
These new 3rd generation CAR T's are addressing the safety of this type of treatment.
The good thing for CHM, is that they are at the forefront of this 3rd generation treatment. Yes, this is the future of CAR T treatment, and we are in early with CHM. Paul Hopper is always looking for IP that is the future treatment, and he has done it again here. Adding to CHM other leading platform's we are heading in the right direction.
CHM, grossly under valued, with this world class management team, that's got FDA approval for the first 4 out of 5 CAR T's in the world.
CHM a major in the making, at a bargain price.
- Forums
- ASX - By Stock
- CHM
- Ann: Licenses viral vector technology from Penn for CDH17
Ann: Licenses viral vector technology from Penn for CDH17, page-3
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CHM (ASX) Chart |
Day chart unavailable